Figure 4.
Evolution of pulmonary function (FEV1 in mL) before and after 52-week treatment with mepolizumab 100 mg every 4 weeks. Asterisks indicate statistical significance (** p < 0.01).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.